Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Protocadherin alpha-12 (PCDHA12) is a member of the protocadherin alpha gene cluster, which belongs to the cadherin superfamily of neural cell adhesion molecules. These proteins are integral plasma membrane components, most likely playing critical roles in establishing and maintaining specific cell-cell connections in the brain, especially in neural circuit development. The gene exhibits an unusual genomic organization similar to immune receptor gene clusters, encoding extracellular cadherin domains that mediate homophilic (isoform-specific) and heterophilic cell–cell recognition in the nervous system. Mutations or alteration in PCDHA12 have been associated with autism spectrum disorder and potentially other neurodevelopmental conditions. There is no evidence from available data to classify PCDHA12 as a direct therapeutic target (such as a druggable receptor or enzyme), nor are there any known drugs, biomarkers, or safety issues directly linked to this molecule, though it may be relevant as a biomarker or for genetic research in neurodevelopmental diseases[1][3][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Protocadherin alpha-12 (PCDHA12).